US 12209238
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted A61KA61K48/00
Quick answer
US patent 12209238 (CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 42
- CPC classes
- A61K, A61K48/00